Amirhossein Sakhteman

TOPAS converts phosphoproteomic data into patient-specific reports for molecular tumor boards, focusing on clinically relevant signaling and therapeutic targets.

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

This study uses proteogenomics to show that transposable elements in Blumeria hordei generate novel transcripts and proteins.

The paper uses chemical proteomics to analyze KRAS inhibitor effects on signaling networks in cancer cells, revealing cell-specific responses and phosphorylation changes.

This study identifies ATR inhibitors as synergistic with gemcitabine in killing PDAC cells by blocking the DNA damage response pathway.

This study reanalyzes single-cell RNA sequencing data to show that myeloid-derived suppressor cells in severe COVID-19 patients exhibit upregulated transposable elements, potentially enhancing their suppressive function.

The paper provides a comprehensive proteomic map of 13 human brain regions using high-throughput mass spectrometry, highlighting region-specific protein expression patterns and markers.